- Home
- KNOP vs CLLS Comparison
KNOP vs CLLS Comparison
Compare KNOP & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- CLLS
- Stock Information
- Founded
- KNOP 2013
- CLLS 1999
- Country
- KNOP United Kingdom
- CLLS France
- Employees
- KNOP N/A
- CLLS N/A
- Industry
- KNOP Marine Transportation
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- CLLS Health Care
- Exchange
- KNOP Nasdaq
- CLLS Nasdaq
- Market Cap
- KNOP 316.9M
- CLLS 299.0M
- IPO Year
- KNOP 2013
- CLLS 2007
- Fundamental
- Price
- KNOP $9.21
- CLLS $3.66
- Analyst Decision
- KNOP
- CLLS Buy
- Analyst Count
- KNOP 0
- CLLS 1
- Target Price
- KNOP N/A
- CLLS $8.00
- AVG Volume (30 Days)
- KNOP 88.1K
- CLLS 192.8K
- Earning Date
- KNOP 12-03-2025
- CLLS 11-03-2025
- Dividend Yield
- KNOP 1.13%
- CLLS N/A
- EPS Growth
- KNOP N/A
- CLLS N/A
- EPS
- KNOP 0.69
- CLLS N/A
- Revenue
- KNOP $332,137,000.00
- CLLS $63,438,000.00
- Revenue This Year
- KNOP $11.88
- CLLS N/A
- Revenue Next Year
- KNOP $2.04
- CLLS $66.76
- P/E Ratio
- KNOP $13.34
- CLLS N/A
- Revenue Growth
- KNOP 12.14
- CLLS 223.09
- 52 Week Low
- KNOP $5.28
- CLLS $1.10
- 52 Week High
- KNOP $9.93
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- KNOP 59.51
- CLLS 50.86
- Support Level
- KNOP $8.71
- CLLS $3.43
- Resistance Level
- KNOP $9.44
- CLLS $3.71
- Average True Range (ATR)
- KNOP 0.35
- CLLS 0.33
- MACD
- KNOP 0.03
- CLLS -0.09
- Stochastic Oscillator
- KNOP 84.03
- CLLS 12.92
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.